Immunotherapy before surgery: which next step works best for lung cancer?
NCT ID NCT07166003
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 500 lung cancer patients who received immunotherapy before their main treatment. Researchers want to see whether surgery (removing part or all of a lung) or non-surgery options like radiation lead to better long-term outcomes. The goal is to find the best approach after initial immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-tumor drugs (immunotherapy)
What this could lead to
If successful, this study could help doctors choose the best treatment after immunotherapy for lung cancer, potentially improving survival and reducing complications.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NON-SMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••